Protocol Title: TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients with Metastatic Castration Resistant Prostate Cancer Associated with Homologous Recombination Deficiency

Target Population: Metastatic Castration-Resistant Prostate Cancer

Summary: The purpose of this study is to determine how patients with Metastatic Castration-Resistant Prostate Cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with Rucaparib versus treatment with physician's choice of Abiraterone Acetate, Enzalutamide, or Docetaxel.

Key Inclusion Criteria:
- Be 18 years old at the time the informed consent is signed
- Have a histologically or cytologically confirmed Adenocarcinoma or Poorly Differentiated Carcinoma of the Prostate
- Be surgically or medically castrated, with serum Testosterone levels of ≤ 50 ng/dL (1.73 nM)
- Be eligible for treatment with physician's choice of comparator treatment (Abiraterone Acetate, Enzalutamide or Docetaxel)
- Experienced disease progression after having received 1 prior next generation androgen receptor-targeted therapy for Castration-Resistant disease
- Have a deleterious mutation in a BRCA1/2 or ATM gene

Key Exclusion Criteria:
- Active second malignancy, with the exception of curatively treated non melanoma skin cancer, carcinoma in situ, or superficial bladder cancer
- Prior treatment with any PARP Inhibitor
- Prior treatment with chemotherapy for Metastatic Castration-Resistant Prostate Cancer
- Symptomatic and / or untreated Central Nervous System metastases
- Pre-existing duodenal stent and / or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of study drug

Contacts:
- Principal Investigator: Marc Matrana, MD
- Research Nurses (RN): Jessica Rentfrow (jessica.rentfrow@ochsner.org, ext. 32652)
  Amanda Struckhoff (amanda.struckhoff@ochsner.org, ext. 23682)

For additional information: https://clinicaltrials.gov/ct2/show/NCT02975934